Lawrence R. McGee, et al. Application No.: 09/606,433 Page 2 **PATENT**

031

8 43.

(Amended) A compound of claim 1, having the formula:

B2

(Twice Amended) A composition comprising a pharmaceutically acceptable excipient and a compound of any one of claims 1, 2, 4=5, and 43.

(Twice Amended) A method for treating a condition mediated by PPARγ in a host, said method comprising administering to said host an efficacious amount of a compound of any one of claims 1, 2, 48, and 43.

133

28 66. (Twice A

(Twice Amended) A compound of any of claims 1, 2, 4-8, and 43,8

wherein said compound is a modulator of PPARy.

REMARKS

Claims 1, 2, 4-8, 43, 46-53, and 55-67 are presented for examination. Claims 43, 46, 47, and 66 are amended. Claim 44 is canceled without prejudice.

Amendments to the Claims

The amendments to the claims add no new matter.

Claim 43 was amended to delete a recital of one of the two members of the Markush group.

Claims 46, 47 and 66 were amended to remove the recital of canceled claim 44 from their multidependency recitals.

PATENT

Lawrence R. McGee, et al. Application No.: 09/606,433

Page 3

As the Amendments to the claims add no new matter, Applicants respectfully request their entry.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5012.

Respectfully submitted,

Frank J. Mycroft Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor

San Francisco, California 94111-3834

Tel: 925-472-5000 Fax: (415) 576-0300

FJM:mmm WC 9046833 v1

PATENT

Lawrence R. McGee, et al. Application No.: 09/606,433 Page 4

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claim 44 has been canceled without prejudice.

Claims 43, 46, 47, and 66 have been amended as follows:

43. (Amended) A compound of claim 1, [selected from the group consisting of] having the formula:

- 46. (Twice Amended) A composition comprising a pharmaceutically acceptable excipient and a compound of any one of claims 1, 2, 4-8, and 43[, and 44].
- 47. (Twice Amended) A method for treating a condition mediated by PPARγ in a host, said method comprising administering to said host an efficacious amount of a compound of any one of claims 1, 2, 4-8, and 43[, and 44].
- (Twice Amended) A compound of any of claims 1, 2, 4-8, and 43[, and
 wherein said compound is a modulator of PPARγ.